Moderna Shares Struggle Despite Government Funding Boost

Moderna ( (MRNA) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.

Moderna’s stock has been struggling, despite a recent 4% uptick following a $590 million boost from the U.S. government for bird flu vaccine development. This funding marks a strong federal commitment to pandemic preparedness, supporting late-stage development of Moderna’s mRNA-based bird flu vaccine. However, the stock has faced a 66% decline over the past year, largely due to a steep drop in Covid-19 vaccine sales and uncertainty surrounding future revenues. Analysts have adjusted price targets based on Moderna’s revised financial guidance and the biotech sector’s cautious market outlook.

More about Moderna

YTD Price Performance: -19.62%

Average Trading Volume: 8,986,984

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $12.99B

For further insights into MRNA stock on TipRanks’ Stock Analysis page.

See more of today’s top stock gainers and losers.